In the low-tumor-marker group (post-treatment PIVKA-II ≤ 40 mAU/mL), AFP levels significantly decreased from 3.0 ng/mL to 1.5 ng/mL (p = 0.001), but PIVKA-II levels remained relatively unchanged, increasing slightly from 25.0 mAU/mL to 28.0 mAU/mL (p = 0.932), as shown in Table 3b. The gene discussed is AFP; the disease is neoplasm.